Clinical trial · Interventional
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment, A Pilot Study
NCT00387062CI-TRIAL-00001550completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hypothesize that continuous active interaction with environments that are demanding to sensory, cognitive, and motor systems, together with imbedded rewards for successful performance, will help improve memory and cognitive functioning in patients suffering from "chemobrain".
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cognitive Symptoms | — | UNRESOLVED | — |
| Memory Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computer-based Cognitive Training | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Examination of the quantitative training program progression data
- measure
- Safety
Secondary outcomes (3)
- measure
- Quality of life health assessments
- measure
- Functional outcomes assessments
- measure
- Perceived stress assessments
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Age 21 or older at the time of consent. * Diagnosis of invasive breast cancer or recurrence warranting treatment with chemotherapeutic agents in the past 5 years. * Cognitive decline, as reported by the patient, friends, or family. * Fluent English speaker. * Willing and able to commit to the 6-month time requirement of the entire study period. * Willing to provide informed consent * Willing to participate in training of the program. * Agrees to weekly contact Exclusion Criteria: * Severe hearing impairments that would: * limit the ability to receive instructions and support; and * hinder performance on the computer training program. * Self-report of untreated Axis I or II disorders (with the exception of depression, anxiety disorders, and panic disorders). * Self-report of current diagnosis or history of major neurological illness including, but not limited to: * Alzheimer's disease * Parkinson's disease * Multiple sclerosis * Amyotrophic lateral sclerosis * History of a stroke, transient ischemic attack (TIA) or traumatic brain injury within the past year; or lifetime history of stroke, TIA, or traumatic brain injury that has left residual expressive or receptive language problems. * Self-report of fibromyalgia or symptoms of tremor severe enough to prevent the use of a computer mouse or other pointing device. * Unwillingness to complete the required assessments. * Patient is not capable of giving informed consent or unable to comprehend and/or follow instructions.
References
Publications (23)
- BACKGROUNDShilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007 Feb;11(1):6-15. doi: 10.1016/j.ejon.2006.02.005. Epub 2006 Jul 17. PMID 16844416
- BACKGROUNDWefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004 Aug 1;101(3):466-75. doi: 10.1002/cncr.20393. PMID 15274059
- BACKGROUNDTannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004 Jun 1;22(11):2233-9. doi: 10.1200/JCO.2004.08.094. PMID 15169812
- BACKGROUNDSchagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FS. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002 Sep;13(9):1387-97. doi: 10.1093/annonc/mdf241. PMID 12196364
- BACKGROUNDvan Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998 Feb 4;90(3):210-8. doi: 10.1093/jnci/90.3.210. PMID 9462678
- BACKGROUNDSchagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999 Feb 1;85(3):640-50. doi: 10.1002/(sici)1097-0142(19990201)85:33.0.co;2-g. PMID 10091737
- BACKGROUNDBrezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000 Jul;18(14):2695-701. doi: 10.1200/JCO.2000.18.14.2695.